EA201791118A1 - Кодон-оптимизированный полинуклеотид для экспрессии crmна высоком уровне - Google Patents

Кодон-оптимизированный полинуклеотид для экспрессии crmна высоком уровне

Info

Publication number
EA201791118A1
EA201791118A1 EA201791118A EA201791118A EA201791118A1 EA 201791118 A1 EA201791118 A1 EA 201791118A1 EA 201791118 A EA201791118 A EA 201791118A EA 201791118 A EA201791118 A EA 201791118A EA 201791118 A1 EA201791118 A1 EA 201791118A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crm
expression
high level
codon
polynucleotide
Prior art date
Application number
EA201791118A
Other languages
English (en)
Other versions
EA035117B1 (ru
Inventor
Гоэл Акшай
Нараян Мишра Рави Пратар
Мантена Нарендер Дев
Датла Махима
Original Assignee
Байолоджикал И Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байолоджикал И Лимитед filed Critical Байолоджикал И Лимитед
Publication of EA201791118A1 publication Critical patent/EA201791118A1/ru
Publication of EA035117B1 publication Critical patent/EA035117B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)

Abstract

Настоящее изобретение относится к экспрессии на высоком уровне бактериального токсоида или белка-токсина, представляющего фармакологический интерес, посредством оптимизированной новой полинуклеотидной последовательности, и к хозяину, трансформированному указанным полинуклеотидом. В частности, изобретение относится к способу высокой продукции полипептида CRM, где полинуклеотид по изобретению используют для трансформации подходящего хозяина, что приводит к сверхэкспрессии соответствующих белков, и к способу выделения экспрессируемого полипептида. Более конкретно, настоящее изобретение относится к экспрессии CRMна высоком уровне Escherichia coli и к способу его выделения и очистки.
EA201791118A 2014-11-20 2015-11-17 Кодон-оптимизированный полинуклеотид для экспрессии crmна высоком уровне EA035117B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4045CH2014 2014-11-20
PCT/IN2015/000427 WO2016079755A1 (en) 2014-11-20 2015-11-17 Codon optimized polynucleotide for high level expression of crm197

Publications (2)

Publication Number Publication Date
EA201791118A1 true EA201791118A1 (ru) 2017-10-31
EA035117B1 EA035117B1 (ru) 2020-04-29

Family

ID=55346156

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791118A EA035117B1 (ru) 2014-11-20 2015-11-17 Кодон-оптимизированный полинуклеотид для экспрессии crmна высоком уровне

Country Status (11)

Country Link
US (1) US10280409B2 (ru)
EP (1) EP3221339A1 (ru)
JP (2) JP2017538444A (ru)
CN (1) CN107109416A (ru)
AU (1) AU2015348922B2 (ru)
CA (1) CA2968491C (ru)
EA (1) EA035117B1 (ru)
MX (1) MX2017006506A (ru)
SA (1) SA517381488B1 (ru)
WO (1) WO2016079755A1 (ru)
ZA (1) ZA201703150B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11147863B2 (en) 2015-06-23 2021-10-19 Biological E Limited Multivalent pneumococcal conjugate vaccine
NZ752348A (en) 2016-09-30 2022-11-25 Biological E Ltd Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
WO2019043593A1 (en) * 2017-09-01 2019-03-07 Lorven Biologics Private Limited NUCLEIC ACID ENCODING CRM197 AND ENHANCED EXPRESSION PROCESS THEREOF
KR20200111685A (ko) * 2018-01-19 2020-09-29 오비아이 파머 인코퍼레이티드 Crm197 단백질 발현
WO2020033398A1 (en) * 2018-08-06 2020-02-13 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating atii cell-dependent lung diseases
KR102142255B1 (ko) * 2019-12-05 2020-08-07 주식회사 제노포커스 Crm197 단백질 발현 방법
GB202108650D0 (en) * 2021-06-17 2021-08-04 Inst De Medicina Molecular Joaeo Lobo Antunes Production of cross-reactive material 197 fusion proteins
KR20230102682A (ko) * 2021-12-30 2023-07-07 (주)셀트리온 목적 단백질의 발현 방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755465A (en) 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US5281532A (en) 1983-07-27 1994-01-25 Mycogen Corporation Pseudomas hosts transformed with bacillus endotoxin genes
US4695462A (en) 1985-06-28 1987-09-22 Mycogen Corporation Cellular encapsulation of biological pesticides
US4695455A (en) 1985-01-22 1987-09-22 Mycogen Corporation Cellular encapsulation of pesticides produced by expression of heterologous genes
US5128130A (en) 1988-01-22 1992-07-07 Mycogen Corporation Hybrid Bacillus thuringiensis gene, plasmid and transformed Pseudomonas fluorescens
US5055294A (en) 1988-03-03 1991-10-08 Mycogen Corporation Chimeric bacillus thuringiensis crystal protein gene comprising hd-73 and berliner 1715 toxin genes, transformed and expressed in pseudomonas fluorescens
US5169760A (en) 1989-07-27 1992-12-08 Mycogen Corporation Method, vectors, and host cells for the control of expression of heterologous genes from lac operated promoters
ES2231770T3 (es) 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
US20060270600A1 (en) 2005-05-26 2006-11-30 Eisuke Mekada Anti-cancer agents
NZ569168A (en) * 2005-12-22 2012-02-24 Glaxosmithkline Biolog Sa Streptococcus pneumoniae polysaccharide conjugate vaccine comprising 19F-DT conjugate
IT1398927B1 (it) * 2009-06-25 2013-03-28 Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
GB0917647D0 (en) * 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
JP5839411B2 (ja) 2010-03-30 2016-01-06 フェニックス インク． 組み換え型毒素タンパク質の高レベルの発現
GB201106225D0 (en) 2011-04-13 2011-05-25 Glaxosmithkline Biolog Sa Fermentation process
GB201209896D0 (en) 2012-06-01 2012-07-18 Fujifilm Diosynth Biotechnologies Uk Ltd Process
CN102766647A (zh) * 2012-07-25 2012-11-07 天津康希诺生物技术有限公司 在白喉杆菌中稳定复制的表达载体及含该载体的白喉杆菌
EP2938363B1 (en) * 2012-12-27 2019-08-21 GlaxoSmithKline Biologicals S.A. Methods and compositions relating to crm197
CN103266125A (zh) * 2013-06-04 2013-08-28 北京民海生物科技有限公司 白喉毒素突变体crm197的制备方法
KR102315246B1 (ko) 2014-03-03 2021-10-21 스캐랩 게노믹스, 엘엘씨 대장균에서 재조합 ｃｒｍ197의 향상된 생산

Also Published As

Publication number Publication date
EA035117B1 (ru) 2020-04-29
EP3221339A1 (en) 2017-09-27
MX2017006506A (es) 2018-03-12
AU2015348922B2 (en) 2020-01-23
JP2020171307A (ja) 2020-10-22
WO2016079755A1 (en) 2016-05-26
AU2015348922A8 (en) 2019-03-14
JP7042305B2 (ja) 2022-03-25
US10280409B2 (en) 2019-05-07
BR112017010718A2 (pt) 2017-12-26
SA517381488B1 (ar) 2021-10-17
AU2015348922A1 (en) 2017-06-01
US20170306302A1 (en) 2017-10-26
CA2968491C (en) 2023-09-26
CN107109416A (zh) 2017-08-29
ZA201703150B (en) 2019-05-29
JP2017538444A (ja) 2017-12-28
CA2968491A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
EA201791118A1 (ru) Кодон-оптимизированный полинуклеотид для экспрессии crmна высоком уровне
MX2023011785A (es) Metodos y composiciones para produccion de proteina de clara de huevo.
EP3741849A3 (en) Protease variants and polynucleotides encoding same
MX2017016811A (es) Metodos para mejorar el rendimiento del animal.
MX2020010841A (es) Composicion detergente.
EP3708660A3 (en) Polypeptides
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
BR112017006736A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes, e métodos de utilização
MX2016016886A (es) Anticuerpos anti-axl.
TR201909037T4 (tr) Yeni protein deamidaz.
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
SA515361251B1 (ar) طريقة لزيادة تكوين حمض بيرو-جلوتاميك من بروتين
EA201692025A1 (ru) Доставка белков, осуществляемая на основе бактерий
EA201791424A1 (ru) Получение белка
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
MX2020003508A (es) Un factor de secrecion de proteinas con alta eficacia secretora y un vector de expresion que lo comprende.
EA201892624A1 (ru) Растения, дающие бессемянные плоды
EA201990034A1 (ru) Ферментативное гликозилирование стевиолгликозидов и других соединений с глюкозо-1-фосфатом
EA201890710A1 (ru) Способ очистки гидролизата биомассы
MX2017008908A (es) Proceso para la hidrólisis de queratina empleando proteasas.
MX2022009064A (es) Procedimiento para preparar una composicion de consome que puede ser bombeada.
EP3701036A4 (en) METHOD OF MANUFACTURING RECOMBINANT E. COLI
RU2017141773A (ru) Микроорганизм рода Escherichia, продуцирующий L-триптофан, и способ получения L-триптофана с его использованием
EA201692439A1 (ru) Пролин-специфичная эндопротеаза и ее применение